GlycoFi

About GlycoFi

GlycoFi, Inc. was a biotechnology firm specializing in yeast glycoengineering, a proprietary technology for producing optimized biologic drug molecules. The company was founded in 2000 by Dartmouth Professors Tillman Gerngross and Charles Hutchinson. Gerngross, a bioengineering professor with a Ph.D. in Molecular Biology, served as Chief Scientific Officer, leveraging his research on engineering yeast cells to produce human-like proteins. The company's core technology involved engineering strains of yeast, specifically *Pichia pastoris*, to create proteins with specific, human-like carbohydrate side chains, a process known as glycosylation. This method offered advantages in speed, cost, and quality over traditional manufacturing methods for therapeutic proteins like monoclonal antibodies.

The company's business model focused on leveraging its protein optimization platform to develop and commercialize biotherapeutics, both independently and through partnerships with major biopharmaceutical companies like Eli Lilly. GlycoFi operated as a venture-backed, private company with investors including Polaris Venture Partners, SV Life Sciences, and Boston Millennia Partners. Its primary market was the biopharmaceutical industry, providing a more efficient platform for discovering and developing novel drugs and vaccines, particularly in therapeutic areas like oncology.

A key achievement was the complete humanization of the glycosylation pathway in yeast, enabling the production of therapeutic proteins with improved performance and manufacturing efficiency. After establishing a research collaboration with Merck & Co. in late 2005, GlycoFi was acquired by the pharmaceutical giant in May 2006 for approximately $400 million in an all-cash transaction. Following the acquisition, GlycoFi became a wholly-owned subsidiary of Merck, continuing its operations in Lebanon, New Hampshire, to integrate its technology with Merck's research and development capabilities in vaccines and biologics.